ASH 2024: Advancing the Multiple Myeloma Landscape

Saad Z. Usmani, MD, MBA, FACP, discusses how the latest findings from studies presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition, including the AQUILA, MajesTEC-5, and iMMagine-1 trials, highlight the potential of early intervention, bispecific antibodies, and chimeric antigen receptor T-cell therapies to transform the treatment landscape for multiple myeloma.